First-in-Class Bispecific Nanobody Targeting LPAM-1 and TNFSF15 for Inflammatory Bowel Disease Intervention

VHH-P802 is a humanized bispecific nanobody developed to simultaneously target Integrin alpha4beta7 (LPAM-1) receptor and TNF superfamily member 15 (TNFSF15). Currently in the biological testing stage, this innovative antibody construct is engineered to address the complex pathophysiology of inflammatory bowel disease by modulating key pathways implicated in immune cell trafficking and inflammatory signaling. VHH-P802 leverages the distinct biological roles of LPAM-1 and TNFSF15, representing a new therapeutic strategy designed to provide improved efficacy and disease control for patients impacted by inflammatory bowel disease.

Licensing Opportunity

VHH-P802 is available for partnering and out-licensing opportunities. Organizations seeking to advance innovative treatments for inflammatory bowel disease are invited to inquire about collaboration and commercialization prospects for this first-in-class bispecific nanobody.

Development Phase

Modality

VHH-P802 consists of a bispecific construct comprising two single domain antibodies (nanobodies) that independently target TL1A and integrin alpha4beta7. Nanobodies are characterized by their small molecular size, robust stability, and exceptional tissue penetration, features that facilitate access to difficult-to-reach targets within inflamed gastrointestinal tissues. This advanced modular structure enables simultaneous blockade of two independent pathogenic pathways, potentially leading to greater clinical benefit in complex inflammatory conditions such as inflammatory bowel disease. The design also offers increased molecular stability and manufacturability compared to conventional antibody formats, supporting versatile product development and broad therapeutic reach.

Target

LPAM-1 and TNFSF15 are key molecular targets driving the pathogenesis of inflammatory bowel disease. LPAM-1 is a cell surface integrin mainly expressed on lymphocytes, mediating gut-specific homing by facilitating adhesion to mucosal addressins. TNFSF15 is a cytokine of the tumor necrosis factor superfamily, expressed by multiple cell types, and is involved in amplifying inflammatory responses in the gastrointestinal tract. Both LPAM-1 and TNFSF15 are strongly implicated in leukocyte trafficking and pro-inflammatory signaling in inflammatory bowel disease. Their selective inhibition by VHH-P802 can disrupt critical inflammatory cascades, offering a dual-targeted strategy of significant value. Targeting both LPAM-1 and TNFSF15 enhances the likelihood of achieving comprehensive disease control and positions VHH-P802 as a strategically differentiated therapeutic asset for inflammatory bowel disease.

Mechanism of Action

VHH-P802 exerts its therapeutic effects via dual blockade of LPAM-1 and TNFSF15 mediated pathways. By binding LPAM-1, VHH-P802 interferes with lymphocyte adhesion and migration into inflamed gut tissue, a central mechanism in the pathogenesis of inflammatory bowel disease. Concurrently, antagonism of TNFSF15 suppresses pro-inflammatory signal transduction, dampening cytokine cascades that perpetuate mucosal damage. This combinatorial approach modulates immune cell trafficking as well as local inflammatory signaling. The bispecific nanobody format offers a highly adaptable platform with potential for derivation into multi-functional therapeutics, supporting modalities such as antibody-drug conjugates and other engineered bispecific constructs for expanded immunological applications.

Inflammatory Bowel Disease

Inflammatory bowel disease comprises chronic, relapsing-remitting inflammatory disorders of the gastrointestinal tract, most notably Crohn's disease and ulcerative colitis. The global burden of disease continues to rise, affecting diverse populations and representing a major public health challenge. Standard treatments include immunosuppressants, systemic corticosteroids, and biologic therapies that target key drivers of the inflammatory cascade. Despite advances in targeted therapy, many patients remain refractory or experience significant adverse effects, highlighting an unmet need for safer, more effective interventions. VHH-P802's bispecific inhibition of LPAM-1 and TNFSF15 offers a rational strategy to address the multifactorial pathophysiology of inflammatory bowel disease, with the promise of improved efficacy and minimization of systemic toxicity through localized action and precise immunomodulation.